The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.
Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.
By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.
Christophe De Block studied medicine at the University of Antwerp, Antwerp, Belgium and graduated magna cum laude. He is Head of the Department of Endocrinology-Diabetology & Metabolism at Antwerp University Hospital, Full Professor at the University of Antwerp, and Former President of the Diabetes Liga Belgium.
Prof. De Block’s main clinical and research interests are related to prediction and prevention of type 1 diabetes, autoimmune polyendocrine syndromes, and new treatment options for diabetes, including incretin-based therapies. His latest field of interest focusses on the application of continuous glucose monitoring, functional insulin therapy, and sensor-augmented pump therapy.
Prof. De Block has received several scientific awards, including the Award of the Royal Academy of Medicine of Belgium for experimental investigations on autoimmune diseases, the Young Investigator’s Award of the Belgian Endocrine Society in 2005, and the Novo Nordisk Award for Diabetes 2015–2016. He has published more than 150 papers in international medical journals.
Prof. De Block is a member of the European Association for the Study of Diabetes, the American Diabetes Association, the Endocrine Society, the Belgian Diabetes Registry, and the Belgian Endocrine Society.